Navigation Links
Sorafenib Slows Growth of Some Leukemias
Date:2/1/2008

Drug shows potential for patients with specific gene mutations, researchers find

FRIDAY, Feb. 1 (HealthDay News) -- The drug sorafenib shows promise in the treatment of people with acute myeloid leukemia who have specific gene mutations, say U.S. researchers.

Previous research has shown that sorafenib -- currently used to treat kidney and liver cancer -- is effective against acute myeloid leukemia cells that have internal tandem duplication (ITD) mutations of the Fms-like tyrosine kinase 3 (FLT3) gene, according to background information in the study.

Researchers at the University of Texas M.D. Anderson Cancer Center in Houston looked at sorafenib's effect on leukemia cells that express either the common or mutant copies of FLT3. They also gave the drug to mice with leukemia cells with known FLT3 mutations and to leukemia patients with and without the FLT3 mutation.

Sorafenib slowed growth and induced cell death in the FLT3 mutant leukemia cells and increased survival of the mice with FLT3 mutant leukemia. The drug also reduced the percentage of leukemia cells in the blood and marrow of leukemia patients with the FLT3 mutation but not in leukemia patients without the mutation.

"Our findings imply that sorafenib is a potent anti-leukemic agent in patients with FLT3-ITD mutant [acute myeloid leukemia], a form of [the disease] that responds poorly to traditional chemotherapy," the study authors concluded.

The findings were published in the Jan. 29 issue of the Journal of the National Cancer Institute.

More information

The American Cancer Society has more about acute myeloid leukemia.



-- Robert Preidt



SOURCE:Journal of the National Cancer Institute, news release, Jan. 29, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Health Insurance Premium Growth Slows for Fourth Straight Year
2. Philanthropic Giving for Health Care Slows in 2006 in both U.S. and Canada, According to Association for Healthcare Philanthropys Annual Report on Giving
3. Drug slows prostate tumor growth by keeping vitamin A active
4. Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses
5. High pollution linked to poor lung function growth in children in Mexico City
6. Researchers develop long-lasting growth hormone
7. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
8. Plexus Systems Ranks in Top Third of the 2007 Inc. 5,000 with Three-Year Sales Growth of 226%
9. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
10. AWT Management Announce Aggressive Growth and Acquisition Strategy
11. Cynosure to Present at the Maxim Group Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sorafenib Slows Growth of Some Leukemias
(Date:10/12/2017)... ... 12, 2017 , ... HMP , a leader in healthcare events and ... Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie ... annual award competition recognizes editorial and design excellence across a range of sectors. This ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations ... literacy software tool, and the Cancer Patient Education Network (CPEN), an independent professional ... announce a new strategic alliance. , As CPEN’s strategic partner, HLI will ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... the latest in wound care advancements to physician colleagues, skilled nursing facility medical ... titled, "Navigating the Treacherous Waters of Wound Care." , "At many of these ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vodori, Inc., ... promotional review platform at the Promotional Review Committee Compliance and Best Practices ... streamline the medical, legal, and regulatory review (MLR) process – which ensures ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
(Date:10/2/2017)... 2, 2017  AllianceRx Walgreens Prime, the combined central ... and pharmacy benefit manager Prime Therapeutics LLC (Prime), today ... included the unveiling of new signage at its headquarters ... as at a few other company-owned facilities across the ... patients, some of whom will begin to see the ...
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
Breaking Medicine Technology: